Earnings Data
Report Date
Jul 16, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
1.04Last Year’s EPS
1.02Same Quarter Last Year
Strong Buy
Based on 20 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a generally positive outlook driven by solid device performance, completion and strategic value of the Exact Sciences acquisition (adding ~$3 billion of sales), strong pipeline progress, and underlying comparable sales and EPS growth. However, near-term headwinds remain: a notably weak respiratory season that hit molecular testing, ongoing Nutrition volume recovery, China VBP lingering effects, and modest EPS dilution from the acquisition. Management emphasized confidence in execution and an expectation of growth acceleration in the second half of the year, balancing near-term caution with medium- to long-term upside.Company Guidance
Adjusted EPS and Guidance
Adjusted EPS of $1.15 in Q1 2026, up 6% year-over-year. Q2 adjusted EPS guidance of $1.25 to $1.31. Full-year adjusted EPS guidance midpoint revised to $5.48 (reflecting $0.20 dilution from Exact Sciences acquisition).
Comparable Sales Growth
First quarter sales increased 3.7% on a comparable basis. Full-year 2026 sales growth outlook set at 6.5% to 7.5% on a comparable basis (includes Exact Sciences in both prior and current year).
Exact Sciences Acquisition Completed
Acquisition of Exact Sciences closed March 23, 2026; management expects approximately $3 billion of incremental sales in 2026 and that the asset will accelerate Abbott's long-term sales growth. Integration described as progressing well with dedicated leadership and standalone reporting into Diagnostics.
Strong Medical Devices Performance
Medical Devices sales grew 8.5% in Q1. Electrophysiology up 13% (including two PFA catheter launches), Rhythm Management up 13% (third consecutive quarter of double-digit growth), and Heart Failure up 12%.
Diagnostics Strength in Cancer and Core Lab
Cancer Diagnostics grew 13% on a comparable basis (Cologuard mid‑teens US growth and high‑teens internationally). Core Lab Diagnostics grew 3% driven by the U.S., Europe and Latin America; management expects Core Lab full-year mid‑single digit growth.
EP Product Launch Momentum
Earlier-than-planned approvals and limited-market launches for two PFA catheters (Volt in U.S., TactiFlex Duo in Europe) with favorable early feedback; management expects EP growth to accelerate and to outpace market exit rates.
CGM Business Scale and Long-Term Opportunity
CGM sales were $2.0 billion in Q1, up 7.5% (management expects return to double-digit growth in Q2). Management cites a global addressable population of 70–80 million vs. current market of ~10–12 million and anticipates near-term reimbursement catalysts (CMS type 2 non‑insulin) that could add ~10 million covered lives.
R&D and Pipeline Progress
Notable pipeline achievements: completion of enrollment in Catalyst LAAC trial, initiation of extravascular ICD development, positive RCT for Libre in type 2 diabetes on basal insulin (reductions in HbA1c and increased time-in-range), and upcoming trials/products including balloon-expandable TAVR, leadless conduction pacing, Cephea mitral replacement valve, peripheral IVL, and a wearable lactate sensor.
Favorable Foreign Exchange Impact
Foreign exchange had a favorable year-over-year impact of ~4% on Q1 sales; management expects FX to be roughly +1% on full-year reported sales and relatively neutral in Q2.
CH:ABT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CH:ABT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 16, 2026 | CHF80.00 | CHF77.00 | -3.75% |
Jan 22, 2026 | CHF99.40 | CHF99.40 | 0.00% |
Oct 15, 2025 | CHF100.41 | CHF100.88 | +0.46% |
Jul 17, 2025 | CHF104.35 | CHF104.35 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Abbott Laboratories (CH:ABT) report earnings?
Abbott Laboratories (CH:ABT) is schdueled to report earning on Jul 16, 2026, Before Open (Confirmed).
What is Abbott Laboratories (CH:ABT) earnings time?
Abbott Laboratories (CH:ABT) earnings time is at Jul 16, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Abbott Laboratories stock?
The P/E ratio of Abbott Laboratories is N/A.
What is CH:ABT EPS forecast?
CH:ABT EPS forecast for the fiscal quarter 2026 (Q2) is 1.04.
